Press Releases

Date Title and Summary Additional Formats
Toggle Summary NewLink Genetics HyperAcute® Lung (tergenpumatucel-L) Immunotherapy Demonstrates a Correlation Between Immune Response and Survival in Patients With Non-Small Cell Lung Cancer
NewLink Genetics HyperAcute® Lung (tergenpumatucel-L) Immunotherapy Demonstrates a Correlation Between Immune Response and Survival in Patients With Non-Small Cell Lung Cancer AMES, Iowa, June 4, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq: NLNK ) announced its HyperAcute® Lung
View HTML
Toggle Summary NewLink Genetics Reports Two- and Three-Year Overall Survival Data From Its Phase-2 HyperAcute® Pancreas (algenpantucel-L) Immunotherapy Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
AMES, Iowa, June 4, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq: NLNK ) announces that its HyperAcute® Pancreas (algenpantucel-L) Immunotherapy will be featured today in a poster presentation (abstract number 4049) at the American Society of Clinical Oncology (ASCO) 2012 Annual
View HTML
Toggle Summary Addition of algenpantucel-L immunotherapy to standard of care (SOC) adjuvant therapy for pancreatic cancer View HTML
Toggle Summary Interferon-y (IFN-γ) response correlates with survival in a Phase 2 Hyperacute (tergenpumatucel-L) immunotherapy trial for non-small cell lung cancer (NSCLC) View HTML
Toggle Summary Data From an Investigator-Initiated Phase 2 Study of NewLink Genetics' HyperAcute® Melanoma Immunotherapy Published in 2012 ASCO Annual Meeting Abstracts
HyperAcute Melanoma Demonstrates Activity in Stage III and Stage IV Patients
View HTML
Toggle Summary NewLink Genetics to Present at the Jefferies 2012 Global Healthcare Conference
AMES, Iowa, May 30, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics (Nasdaq:NLNK) announced today that Dr. Charles Link, Chairman and Chief Executive Officer, will present at the Jefferies 2012 Global Healthcare Conference in New York on Wednesday, June 6, 2012, at 4:30 p.m. (EDT). Dr.
View HTML
Toggle Summary Data From NewLink Genetics Phase 2 Trial of Its HyperAcute(R) Pancreas (Algenpantucel-L) Immunotherapy to be Presented at the 2012 Digestive Disease Week
Algenpantucel-L Immunotherapy Phase 2 Data Featured in Plenary Session at 53rd Annual Meeting of the Society for Surgery of the Alimentary Tract and Will be Published in the Journal of Gastrointestinal Surgery
View HTML
Toggle Summary NewLink Genetics Corporation Reports First Quarter 2012 Financial Results
AMES, Iowa, May 10, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today reported consolidated financial results for the first quarter of 2012, and provided an update on the
View HTML
Toggle Summary NewLink Genetics Receives Notice of Allowance From USPTO for New Patent Broadly Covering Its D-1MT IDO Pathway Inhibitor
AMES, Iowa, April 24, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that the United States Patent & Trademark Office (USPTO) has allowed broad claims to oral pharmaceutical compositions comprising 1-methyl-D-tryptophan (D-1MT) (US Serial No.
View HTML
Toggle Summary NewLink Genetics Receives Notice of Allowance From the Japan Patent Office for New Patent Broadly Covering Its HyperAcute(R) Cancer Immunotherapy Products
AMES, Iowa, April 17, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that the Japan Patent Office has issued a notice of allowance for a patent entitled "Antitumor Vaccination Using Allogeneic Tumor Cells Expressing Alpha (1,3)-Galactosyltransferase," which
View HTML